This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignees: Bristol-Myers Squibb Compnay, Janssen Pharmaceutica Nv. Active years: 2025.
Company Filing History:
1 out of 3,737 
1 out of 2,100 
Years Active: 2025
Title: Kostiantyn Chernichenko: Innovator in Pharmaceutical Synthesis
Introduction
Kostiantyn Chernichenko is a notable inventor based in Beerse, Belgium. He has made significant contributions to the field of pharmaceutical synthesis, particularly through his innovative approaches to compound manufacturing. His work has led to the development of a patent that showcases his expertise and creativity in this specialized area.
Latest Patents
Chernichenko holds a patent for "Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one." This patent outlines highly efficient methods for preparing key intermediates in the synthesis of the compound, which are broadly applicable and can provide selected components with various substituent groups.
Career Highlights
Throughout his career, Chernichenko has worked with prominent companies in the pharmaceutical industry. He has been associated with Bristol-Myers Squibb Company and Janssen Pharmaceutica NV, where he has contributed to various projects and advancements in drug development. His experience in these organizations has further solidified his reputation as an innovative thinker in the field.
Collaborations
Chernichenko has collaborated with talented individuals such as Nicolas Cuniere and Yu Fan. These partnerships have allowed him to enhance his research and development efforts, leading to more effective solutions in pharmaceutical synthesis.
Conclusion
Kostiantyn Chernichenko is a distinguished inventor whose work in pharmaceutical synthesis has resulted in valuable patents and collaborations. His innovative methods and contributions continue to impact the industry positively.